News

Quantum Key Distribution – Data Security of the Future?

The UK is at the forefront of developing Quantum Key Distribution (QKD), a revolutionary technology to secure communication in a post-quantum computer world. Discover how QKD works, the challenges it faces, and the ongoing race to build a global secure communication network.

The rise of quantum technology

Over the last few centuries classical physics has been well-equipped to explain the natural phenomena we witness in day-to-day life. In fact it was not until the late 19th century that scientists first began to realise that the characteristics of extremely small systems did not actually seem to reconcile with the accepted laws of classical physics. This led to the advent of quantum mechanical theory - more commonly known as quantum mechanics.

Secerna appointment supports drive for environmental technology

Secerna LLP has been appointed by Sheffield-based global technology group Xeros Technology to support the company’s in-house intellectual property team. Xeros has developed world leading environmentally friendly technologies which are used in garment manufacturing, domestic and commercial laundry, and microfibre filtration.

Get to know Clare Burnard, Secerna Executive Assistant/Office Manager

Get to know Clare Burnard, Secerna Executive Assistant/Office Manager.

Thomas Kennelly - A day in the life of a Part Qualified Patent Attorney

Brexit - Down to the wire

6 Reasons to live and work in Newcastle

Double patenting at the European Patent Office G4/19

The Enlarged Court of Appeal is currently considering a number of issues surrounding double patenting. Secerna Senior Associate Huw Jenkins looks at what they will be looking at. Read more.

PTAB decision highlights the value of a robust IP portfolio

The recent PTAB decision in favor of Arbutus Biopharma highlights the importance of a robust intellectual property portfolio, especially for smaller biotech companies. This case involves Moderna, a leading developer of mRNA vaccines, and their potential infringement of Arbutus' patent on lipid nanoparticle technology, a crucial component of Moderna's COVID-19 vaccine. The decision underscores the potential risks for companies that do not have strong IP protection, as it could limit their ability to develop and commercialize innovative products.